Guardant Health Inc.
Guardant Health Reports 48% Revenue Growth and Raises 2026 Guidance
Summary
Guardant Health, Inc. reported a 48% year-over-year increase in total revenue for the first quarter of 2026, reaching $301.7 million. The company attributed the growth to strong performance in its Oncology and Screening segments. Oncology revenue grew 36% to $205.0 million, while Screening revenue surged over 600% to $41.6 million. Guardant Health also raised its 2026 revenue guidance to a range of $1.30 to $1.32 billion, representing growth of 32% to 34% compared to 2025. The company expects Oncology revenue to grow in the range of 28% to 29%, and Screening revenue to be in the range of $186 to $198 million, driven by Shield volume of 230,000 to 245,000 tests.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement